tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Immix Biopharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns initiated coverage of Immix Biopharma with a Buy rating and $7 price target. Powered by its N-GENUS platform, Immix is advancing potentially differentiated cell therapies, the analyst tells investors in a research note. The firm says NXC-201 has demonstrated encouraging initial results in AL amyloidosis.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1